CETIRIZINE HYDROCHLORIDE ALLERGY

85/100 · Critical

Manufactured by Aurohealth LLC

High Serious Reaction Rate for CETIRIZINE HYDROCHLORIDE ALLERGY

341,924 FDA adverse event reports analyzed

Last updated: 2026-05-12

About CETIRIZINE HYDROCHLORIDE ALLERGY

CETIRIZINE HYDROCHLORIDE ALLERGY is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurohealth LLC. Based on analysis of 341,924 FDA adverse event reports, CETIRIZINE HYDROCHLORIDE ALLERGY has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for CETIRIZINE HYDROCHLORIDE ALLERGY include DRUG INEFFECTIVE, PAIN, FATIGUE, ALOPECIA, ABDOMINAL DISCOMFORT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CETIRIZINE HYDROCHLORIDE ALLERGY.

AI Safety Analysis

Cetirizine Hydrochloride Allergy has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 341,924 adverse event reports for this medication, which is primarily manufactured by Aurohealth Llc.

The most commonly reported adverse events include Drug Ineffective, Pain, Fatigue. Of classified reports, 78.5% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The majority of reactions are non-serious, but the serious reaction rate is high at 78.5%.

A wide range of reactions are reported, indicating potential for diverse side effects. Report volume is substantial, with over 340,000 total reports.

Patients taking Cetirizine Hydrochloride Allergy should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Cetirizine hydrochloride allergy may interact with other drugs, and contraindicated products should be avoided. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.

Safety Score: 85/100

Cetirizine Hydrochloride Allergy received a safety concern score of 85/100 (high concern). This is based on a 78.5% serious event ratio across 28,576 classified reports. The score accounts for 341,924 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.

Top Adverse Reactions

DRUG INEFFECTIVE9,070 reports
PAIN8,608 reports
FATIGUE8,443 reports
ALOPECIA7,261 reports
ABDOMINAL DISCOMFORT7,147 reports
RHEUMATOID ARTHRITIS7,110 reports
SYSTEMIC LUPUS ERYTHEMATOSUS6,850 reports
PEMPHIGUS6,738 reports
RASH6,258 reports
OFF LABEL USE6,257 reports
GLOSSODYNIA6,225 reports
SWELLING5,812 reports
HYPERSENSITIVITY5,433 reports
HAND DEFORMITY5,372 reports
ARTHROPATHY5,298 reports
CONTRAINDICATED PRODUCT ADMINISTERED5,280 reports
INFUSION RELATED REACTION5,256 reports
WOUND5,164 reports
JOINT SWELLING4,976 reports
DRUG INTOLERANCE4,775 reports
HEADACHE4,679 reports
PERICARDITIS4,675 reports
HEPATIC ENZYME INCREASED4,645 reports
ARTHRALGIA4,639 reports
SYNOVITIS4,571 reports
MATERNAL EXPOSURE DURING PREGNANCY4,541 reports
DISCOMFORT4,475 reports
PRODUCT USE ISSUE4,449 reports
PRURITUS4,047 reports
ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE4,043 reports
CONDITION AGGRAVATED3,927 reports
NAUSEA3,653 reports
DYSPNOEA3,575 reports
PYREXIA3,535 reports
URTICARIA3,441 reports
DUODENAL ULCER PERFORATION3,388 reports
TREATMENT FAILURE3,351 reports
HELICOBACTER INFECTION3,348 reports
HYPERTENSION3,272 reports
MALAISE3,201 reports
DIARRHOEA3,196 reports
GENERAL PHYSICAL HEALTH DETERIORATION3,195 reports
VOMITING3,059 reports
THERAPEUTIC PRODUCT EFFECT DECREASED2,993 reports
BLISTER2,959 reports
RHEUMATOID FACTOR POSITIVE2,913 reports
WEIGHT INCREASED2,910 reports
NASOPHARYNGITIS2,884 reports
DIZZINESS2,883 reports
INFECTION2,860 reports
PERIPHERAL SWELLING2,837 reports
MUSCULOSKELETAL STIFFNESS2,759 reports
DRUG HYPERSENSITIVITY2,734 reports
TYPE 2 DIABETES MELLITUS2,718 reports
PSORIATIC ARTHROPATHY2,704 reports
CONFUSIONAL STATE2,603 reports
FOLLICULITIS2,565 reports
LOWER RESPIRATORY TRACT INFECTION2,559 reports
INTENTIONAL PRODUCT USE ISSUE2,529 reports
SINUSITIS2,526 reports
BLOOD CHOLESTEROL INCREASED2,523 reports
IMPAIRED HEALING2,500 reports
IRRITABLE BOWEL SYNDROME2,470 reports
STOMATITIS2,453 reports
ABDOMINAL PAIN UPPER2,451 reports
RHEUMATIC FEVER2,412 reports
HYPOAESTHESIA2,378 reports
MOBILITY DECREASED2,360 reports
LIVER INJURY2,317 reports
MUSCLE INJURY2,239 reports
FIBROMYALGIA2,224 reports
GASTROINTESTINAL DISORDER2,203 reports
INSOMNIA2,169 reports
INJURY2,157 reports
ASTHMA2,144 reports
ILL DEFINED DISORDER2,115 reports
PRODUCT USE IN UNAPPROVED INDICATION2,107 reports
EXPOSURE DURING PREGNANCY2,095 reports
CONTUSION2,054 reports
WHEEZING2,050 reports
PNEUMONIA2,024 reports
ASTHENIA1,961 reports
DECREASED APPETITE1,927 reports
SWOLLEN JOINT COUNT INCREASED1,874 reports
PAIN IN EXTREMITY1,803 reports
SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, INSOMNIA TYPE1,767 reports
ANXIETY1,710 reports
SLEEP DISORDER1,708 reports
CHEST PAIN1,696 reports
MIGRAINE1,685 reports
WEIGHT DECREASED1,661 reports
DRY MOUTH1,620 reports
DEPRESSION1,601 reports
DYSPEPSIA1,542 reports
MEMORY IMPAIRMENT1,541 reports
OEDEMA1,524 reports
BURSITIS1,481 reports
OSTEOARTHRITIS1,410 reports
PRESCRIBED OVERDOSE1,398 reports
ABDOMINAL PAIN1,396 reports

Key Safety Signals

  • Rheumatoid arthritis and systemic lupus erythematosus are key safety signals.
  • Multiple reports of serious conditions like pericarditis and hepatic enzyme increased.
  • Drug intolerance and ineffectiveness are frequently reported.

Patient Demographics

Adverse event reports by sex: Female: 18,814, Male: 4,986, Unknown: 22. The most frequently reported age groups are age 43 (1,831 reports), age 44 (1,578 reports), age 40 (836 reports). These demographics reflect reporting patterns and may not represent the full patient population.

Report Outcomes

Out of 28,576 classified reports for CETIRIZINE HYDROCHLORIDE ALLERGY:

  • Serious: 22,419 reports (78.5%) — includes hospitalization, disability, life-threatening events, or death
  • Non-Serious: 6,157 reports (21.5%)
Serious 78.5%Non-Serious 21.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female18,814 (79.0%)
Male4,986 (20.9%)
Unknown22 (0.1%)

Reports by Age

Age 431,831 reports
Age 441,578 reports
Age 40836 reports
Age 59649 reports
Age 58424 reports
Age 56340 reports
Age 50320 reports
Age 62315 reports
Age 71305 reports
Age 48270 reports
Age 60245 reports
Age 65245 reports
Age 64244 reports
Age 57230 reports
Age 42218 reports
Age 67216 reports
Age 45215 reports
Age 61215 reports
Age 72215 reports
Age 36213 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Drug Interactions & Warnings

Cetirizine hydrochloride allergy may interact with other drugs, and contraindicated products should be avoided.

What You Should Know

If you are taking Cetirizine Hydrochloride Allergy, here are important things to know. The most commonly reported side effects include drug ineffective, pain, fatigue, alopecia, abdominal discomfort. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Consult a healthcare provider if experiencing severe or persistent side effects. Report any adverse reactions to the FDA's MedWatch program. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.

Regulatory Context

The FDA continues to monitor cetirizine hydrochloride allergy for safety concerns, with ongoing reviews.

Frequently Asked Questions

How many adverse event reports has the FDA received for Cetirizine Hydrochloride Allergy?

The FDA has received approximately 341,924 adverse event reports associated with Cetirizine Hydrochloride Allergy. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.

What are the most commonly reported side effects of Cetirizine Hydrochloride Allergy?

The most frequently reported adverse events for Cetirizine Hydrochloride Allergy include Drug Ineffective, Pain, Fatigue, Alopecia, Abdominal Discomfort. By volume, the top reported reactions are: Drug Ineffective (9,070 reports), Pain (8,608 reports), Fatigue (8,443 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Cetirizine Hydrochloride Allergy.

What percentage of Cetirizine Hydrochloride Allergy adverse event reports are serious?

Out of 28,576 classified reports, 22,419 (78.5%) were classified as serious and 6,157 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.

Who reports adverse events for Cetirizine Hydrochloride Allergy (by sex)?

Adverse event reports for Cetirizine Hydrochloride Allergy break down by patient sex as follows: Female: 18,814, Male: 4,986, Unknown: 22. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.

What age groups report the most side effects for Cetirizine Hydrochloride Allergy?

The most frequently reported age groups for Cetirizine Hydrochloride Allergy adverse events are: age 43: 1,831 reports, age 44: 1,578 reports, age 40: 836 reports, age 59: 649 reports, age 58: 424 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.

Who manufactures Cetirizine Hydrochloride Allergy?

The primary manufacturer associated with Cetirizine Hydrochloride Allergy adverse event reports is Aurohealth Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.

What other side effects have been reported for Cetirizine Hydrochloride Allergy?

Beyond the most common reactions, other reported adverse events for Cetirizine Hydrochloride Allergy include: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Pemphigus, Rash, Off Label Use. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.

How do I report a side effect from Cetirizine Hydrochloride Allergy?

You can report adverse events from Cetirizine Hydrochloride Allergy to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.

What is Cetirizine Hydrochloride Allergy's safety score and what does it mean?

Cetirizine Hydrochloride Allergy has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The majority of reactions are non-serious, but the serious reaction rate is high at 78.5%.

What are the key safety signals for Cetirizine Hydrochloride Allergy?

Key safety signals identified in Cetirizine Hydrochloride Allergy's adverse event data include: Rheumatoid arthritis and systemic lupus erythematosus are key safety signals.. Multiple reports of serious conditions like pericarditis and hepatic enzyme increased.. Drug intolerance and ineffectiveness are frequently reported.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.

Does Cetirizine Hydrochloride Allergy interact with other drugs?

Cetirizine hydrochloride allergy may interact with other drugs, and contraindicated products should be avoided. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Cetirizine Hydrochloride Allergy.

What should patients know before taking Cetirizine Hydrochloride Allergy?

Consult a healthcare provider if experiencing severe or persistent side effects. Report any adverse reactions to the FDA's MedWatch program.

Are Cetirizine Hydrochloride Allergy side effects well-documented?

Cetirizine Hydrochloride Allergy has 341,924 adverse event reports on file with the FDA. A wide range of reactions are reported, indicating potential for diverse side effects. The volume of reports for Cetirizine Hydrochloride Allergy reflects both the drug's usage level and the vigilance of the reporting community.

What is the FDA's position on Cetirizine Hydrochloride Allergy?

The FDA continues to monitor cetirizine hydrochloride allergy for safety concerns, with ongoing reviews. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.

Other Drugs by Aurohealth LLC

Explore other medications manufactured by Aurohealth LLC and compare their safety profiles:

INFANTS IBUPROFEN (55/100)LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE (45/100)

View all Aurohealth LLC drugs →

Related Drugs

Drugs related to CETIRIZINE HYDROCHLORIDE ALLERGY based on therapeutic use, drug class, or shared indications:

CetirizineLoratadineFexofenadineDesloratadinePseudoephedrine
Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.